Meiyu Geng received her Ph.D. degree from Tokyo University, Japan. She is currently a professor and principal investigator at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Dr. Geng’s research interest is to discover new targeted anticancer therapies. She has played a leading role in the discovery and development of more than ten targeted cancer therapies, particularly small-molecule inhibitors targeting receptor tyrosine kinases and epigenetic modulators, with two having been approved for market in China or overseas. She is the co-inventor of more than 120 domestic or international patents. In parallel to drug discovery, her team is interested to implement precision medicine in drug discovery, particularly to discover molecular biomarkers that inform patient stratification, response assessment and drug resistance management. As the corresponding author, Dr. Geng has published over 170 research articles in peer-reviewed journals including Cell, Cancer Cell, etc. Dr. Geng has received a number of prestigious national awards, such as China Guanghua Engineering Science and Technology Award, Prize of Scientific and Technological Progress of Ho Leung Ho Lee Foundation, Wu Jieping-Paul Janssen Medical & Pharmaceutical Award, 1st Award of Shanghai Outstanding Talents